Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.
Eur J CancerJul 9, 2026 (epub)
Danny Nguyen, Se-Hoon Lee, Shun Lu et al.
✦ AI-curated · Sources linked
In 30 seconds
The phase 3 MARIPOSA study evaluated the efficacy of amivantamab and lazertinib versus osimertinib in patients with untreated, EGFR-mutated advanced non-small cell lung cancer. The study found that the median time to symptomatic progression (TTSP) was significantly longer with the combination therapy at 43.6 months compared to 29.3 months for osimertinib (HR: 0.69; p < 0.0001).
Key findings
- Median TTSP was 43.6 months with amivantamab and lazertinib versus 29.3 months with osimertinib.
- The hazard ratio for TTSP was 0.69, indicating a significant delay in symptomatic progression.
- A strong correlation between TTSP and both progression-free survival and overall survival was observed.
Why it matters
Understanding time to symptomatic progression provides clinicians with a patient-relevant measure of treatment efficacy, enhancing the assessment of therapeutic benefits beyond traditional endpoints like overall survival and progression-free survival.